Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430124 | 0.90 | ALDH1A1 (0.59) | SLC6A7ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL4417060 | 0.88 | SLC6A7 (0.55) | SLC6A7ALDH1A1 | |
| SCHEMBL4415931 | 0.88 | SLC6A7 (0.61) | SLC6A7NAMPTALDH1A1LMNA | |
| SCHEMBL4417361 | 0.84 | SLC6A7 (0.56) | SLC6A7NAMPTALDH1A1LMNAMEN1 | |
| SCHEMBL4422706 | 0.81 | HPGD (0.53) | SLC6A7HPGD | |
| SCHEMBL4423691 | 0.80 | ALDH1A1 (0.51) | SLC6A7ALDH1A1 | |
| SCHEMBL4422851 | 0.80 | SLC6A7 (0.51) | SLC6A7NAMPT | |
| SCHEMBL4419051 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HPGD | |
| SCHEMBL4422930 | 0.78 | SLC6A7 (0.48) | SLC6A7NAMPTALDH1A1LMNAMEN1 | |
| SCHEMBL4422965 | 0.78 | NAMPT (0.51) | SLC6A7NAMPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | SLC6A7 234/4885NAMPT 3332/4885ALDH1A1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.